Saniona's CEO to BioStock: "The deal with Acadia is significant"
Saniona has announced a partnership with Acadia Pharmaceuticals to develop and commercialize SAN711. The total potential deal size is USD 610 million, including an upfront payment of USD 28 million-almost mirroring Saniona's market value before the announcement. BioStock reached out to CEO Thomas Feldthus for a comment.
Read the full interview with Thomas Feldthus at biostock.se:
https://www.biostock.se/en/2024/11/sanionas-ceo-the-deal-with-acadia-is-significant/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/